|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.3358 - 0.4060|
|52 Week Range||0.0940 - 0.4300|
|Beta (5Y Monthly)||1.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
This Definitive Agreement is expected to generate an excess of $47,5M CAD in revenue for TetraOTTAWA, ON / ACCESSWIRE / May 5, 2021 /Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF)(FSE:JAM1), a leader in cannabinoid-derived drug discovery and development announced today the signing of a Definitive Agreement with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™ in Denmark, Norway, Sweden, Finland, and Germany.
A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary settingOTTAWA, ON / ACCESSWIRE / May 4, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development is pleased to announce that it has received authorization from the Veterinary Drugs Directorate of Health Canada for a one year extension to continue the clinical trial evaluating the safety, tolerability and potential efficacy of its veterinary ophthalmic drug, PPP-003v, in the treatment of indolent corneal ulcers in companion animals.
The addressable market in Canada is estimated to be $80M CDN by 2022.Tetra also applies for a Health Canada Cannabis Drug LicenseOTTAWA, ON / ACCESSWIRE / May 3, 2021 / Tetra Bio-Pharma Inc.